Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Expands Russian OTC Foothold Via J.B. Chemicals Portfolio Acquisition

This article was originally published in PharmAsia News

Executive Summary

Johnson & Johnson expands its consumer health presence in Russia and other Eastern European markets with the acquisition of several OTC brands from J.B. Chemicals & Pharmaceuticals

You may also be interested in...



Emerging Views On Emerging Markets: Credit Suisse Healthcare Conference

PharmAsia News takes a closer look at presentations by Baxter, Forest, J&J, Novartis and Zimmer.

J&J And India’s J.B. Chemicals On Collision Course As Sale Of Russian OTC Business Hits Snag

J&J’s sudden claim for funds from an escrow account has sparked speculation on the future of the deal with J.B. Chemicals.

J&J And India’s J.B. Chemicals On Collision Course As Sale Of Russian OTC Business Hits Snag

J&J’s sudden claim for funds from an escrow account has sparked speculation on the future of the deal with J.B. Chemicals.

Related Content

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel